Ask AI
Subcutaneous ICI

CE

Advancing Pharmacist Excellence in Solid Tumors: Essential Considerations for Expanding From IV to Subcutaneous Immune Checkpoint Inhibitors

Pharmacists: 0.75 contact hour (0.075 CEUs)

Released: May 07, 2026

Expiration: November 06, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with cancer do you provide care for in a typical month?

2.

Which best describes your practice setting?

3.

Patient Case 1: 70-Yr-Old With Metastatic RCC



  • Patient NS is a 70-yr-old male with metastatic RCC whose oncologist is recommending axitinib plus pembrolizumab SC

  • NS and his wife have questions about using pembrolizumab SC and wonder whether efficacy and side effects are different between IV and SC

  • His wife is a retired nurse, and she is asking whether she can administer pembrolizumab SC at home

  • Vitals

    • BP: 120/75 mm Hg; height: 5’11”; weight: 170 lb



  • PMH: hypertension, seasonal allergies, osteoarthritis

  • Medications: lisinopril 20 mg QD, cetirizine 10 mg QD, acetaminophen PRN

How would you counsel this patients and his wife about subcutaneous immunotherapy compared with intravenous formulation?

4.

Which of the following could be a potential challenge for successfully implementing use of subcutaneous immunotherapies (ie, atezolizumab, pembrolizumab, or nivolumab)?

5.

Patient Case 2: 60-Yr-Old Female Diagnosed With Metastatic Cutaneous Melanoma



  • Patient CM is a 60-yr-old female diagnosed with metastatic cutaneous melanoma

  • Her oncologist would like to start her on dual immunotherapy with ipilimumab plus nivolumab Q3W x 4 cycles followed by nivolumab Q4W for up to 2 yr

Which of the following is true when considering subcutaneous immunotherapy for this patient who is about to receive combination nivolumab with ipilimumab therapy?